Разгрузочно-диетическая терапия и прерывистое голодание как единая лечебно-профилактическая стратегия возраст-ассоциированных заболеваний человека

Изменение стереотипа питания играет ведущую роль, особенно в качестве «средства» против ожирения и связанных с ним метаболических заболеваний. За последние десятилетия схемы прерывистого голодания приобрели популярность как альтернатива традиционным стратегиям снижения веса, таким как разгрузочно-диетическая терапия и гипокалорийные диеты. Имеющиеся литературные источники свидетельствуют, что прерывистое голодание с учетом конкретных особенностей и потребностей человека может быть рекомендовано как в рамках индивидуальной программы по снижению веса и лечения метаболических заболеваний, так и после длительных циклов разгрузочно-диетической терапии с целью сохранения положительных результатов лечения в отдаленной перспективе. В рамках настоящего обзора показано, что методики низкокалорийного питания, прерывистого и полного голодания являются эффективным нефармакологическим вмешательством для коррекции кардиометаболических нарушений. Они способствуют увеличению продолжительности жизни, подавлению онкогенеза и их целесообразно рассматривать в рамках единой лечебно-профилактической стратегии возраст-ассоциированной патологии человека

1. Ohsumi Y. Historical landmarks of autophagy research. Cell. Res. 2014;24(1):9–23. DOI: 10.1038/cr.2013.169

2. Klionsky D.J., Petroni G., Amaravadi R.K., Baehrecke E.H., Ballabio A., Boya P. et al. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863. DOI: 10.15252/embj.2021108863

3. Silveira Rossi J.L., Barbalho S.M., Reverete de Araujo R., Bechara M.D., Sloan K.P., Sloan L.A. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab. Res. Rev. 2022;38:e3502. DOI: 10.1002/dmrr.3502

4. Максимов В.А. Разгрузочно-диетическая терапия заболеваний органов пищеварения. В кн.: Немедикаментозные методы лечения заболеваний органов пищеварения. М. Адамантъ. 2018:289– 339.

5. Берковская М.А., Гурова О.Ю., Хайкина И.А., Фадеев В.В. Питание, ограниченное по времени, как новая стратегия терапии ожирения и коморбидных состояний. Проблемы эндокринологии. 2022;68(4):78–91.

6. Sharma S.K., Mudgal S.K., Kalra S., Gaur R., Thakur K., Agarwal R. Eff ect of intermittent fasting on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. touchREV Endocrinol. 2023;19(1):25– 32. DOI: 10.17925/EE.2023.19.1.25

7. Shazman S. Understanding type 2 diabetes mellitus risk parameters through intermittent fasting: a machine learning approach. Nutrients. 2023;15(18):3926. DOI: 10.3390/nu15183926

8. Naous E., Achkar A., Mitri J. Intermittent fasting and its eff ects on weight, glycemia, lipids, and blood pressure: a narrative review. Nutrients. 2023;15(16):3661. DOI: 10.3390/nu15163661

9. Aragon A.A., Schoenfeld B.J. Does timing matter? A narrative review of intermittent fasting variants and their eff ects on bodyweight and body Composition. Nutrients. 2022;14(23):5022. DOI: 10.3390/nu14235022

10. Elortegui Pascual P., Rolands M.R., Eldridge A.L., Kassis A., Mainardi F., Lê K.A., Karagounis L.G., Gut P., Varady K.A. A meta-analysis comparing the eff ectiveness of alternate day fasting, the 5:2 diet, and time-restricted eating for weight loss. Obesity. 2023;31(1):9–21. DOI: 10.1002/oby.23568

11. Рекомендации по ведению больных с метаболическим синдромом: клинические рекомендации. М:.2013:43.

12. Jiang Y., Yang X., Dong C., Lu Y., Yin H., Xiao B. et al. Five-day water-only fasting decreased metabolic-syndrome risk factors and increased anti-aging biomarkers without toxicity in a clinical trial of normal-weight individuals. Clin. Transl. Med. 2021;11(8):e502. DOI: 10.1002/ctm2.502

13. Ogłodek E., Pilis W. Is water-only fasting safe? Glob. Adv. Health Med. 2021;10:21649561211031178. DOI: 10.1177/21649561211031178

14. Scharf E., Zeiler E., Ncube M., Kolbe P., Hwang S.Y., Goldhamer A., Myers T.R. The eff ects of prolonged water-only fasting and refeeding on markers of cardiometabolic risk. Nutrients. 2022;14(6):1183. DOI: 10.3390/nu14061183

15. Gabriel S., Ncube M., Zeiler E., Thompson N., Karlsen M.C., Goldman D.M. et al. A six-week follow-up study on the sustained eff ects of prolonged water-only fasting and refeeding on markers of cardiometabolic Risk. Nutrients. 2022;14(20):4313. DOI: 10.3390/nu14204313

16. de Toledo F.W., Grundler F., Bergouignan A., Drinda S., Michalsen A. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects. PLoS One. 2019;14:e0209353. DOI: 10.1371/journal.pone.0209353

17. Schroor M.M., Joris P.J., Plat J., Mensink R.P. Eff ects of intermittent energy restriction compared with those of continuous energy restriction on body composition and cardiometabolic risk markers — a systematic review and meta-analysis of randomized controlled trials in adults. Adv. Nutr. 2024;15(1):100130. DOI: 10.1016/j.advnut.2023.10.003

18. Carter S., Clifton P.M., Keogh J.B. Eff ect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw. Open. 2018;1(3):e180756. DOI: 10.1001/jamanetworkopen.2018.0756

19. Kunduraci Y.E., Ozbek H. Does the energy restriction intermittent fasting diet alleviate metabolic syndrome biomarkers? a randomized controlled trial. Nutrients. 2020;12(10):3213. DOI: 10.3390/nu12103213

20. Петько А.П., Худзиев Б.Г, Михайлов Н.Е., Евдокимов А.С., Исаева О.Л. Роль разгрузочно-диетической терапии в комплексном немедикаментозном лечении гипертонической болезни. Воен.мед. журн. 2015; 336(2): 55–57.

21. Kodela P., Okeke M., Guntuku S., Lingamsetty S.S.P., Slonovschi E. Management of hypertension with non-pharmacological interventions: a narrative review. Cureus. 2023;15(8):e43022. DOI: 10.7759/cureus.43022

22. Ghadieh A.S., Saab B. Evidence for exercise training in the management of hypertension in adults. Can. Fam. Physician. 2015; 61(3): 233–239. [Electronic resource]. URL: https://www.cfp.ca/content/cfp/61/3/233.full.pdf

23. Longo V.D., Mattson M.P. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181–192. DOI: 10.1016/j.cmet.2013.12.008

24. Redman L.M., Smith S.R., Burton J.H., Martin C.K., Il’yasova D., Ravussin E. Metabolic slowing and reduced oxidative damage with sustained caloric restriction support the rate of living and oxidative damage theories of aging. Cell Metab. 2018;27(4):805–815. DOI: 10.1016/j.cmet.2018.02.019

25. Rozing M.P., Westendorp R.G., de Craen A.J., Frölich M., Heijmans B.T., Beekman M. et al. Low serum free triiodothyronine levels mark familial longevity: the Leiden Longevity Study. J. Gerontol. A Biol. Sci. Med. Sci. 2010;65(4):365–368. DOI: 10.1093/gerona/glp200

26. Ravussin E., Redman L.M., Rochon J., Das S.K., Fontana L., Kraus W.E. et al. A 2-year randomized controlled trial of human caloric restriction: feasibility and eff ects on predictors of health span and longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2015;70(9):1097– 1104. DOI: 10.1093/gerona/glv057

27. Stekovic S., Hofer S.J., Tripolt N., Aon M.A., Royer P., Pein L. et al. Alternate day fasting improves physiological and molecular markers of aging in healthy, non-obese humans. Cell Metab. 2019;30(3):462– 476. DOI: 10.1016/j.cmet.2019.07.016

28. Franceschi C., Bonafè M., Valensin S., Olivieri F., De Luca M., Ottaviani E., De Benedictis G. Infl amm-aging. An evolutionary perspective on immunosenescence. Ann. N.Y. Acad. Sci. 2000;908:244–254. DOI: 10.1111/j.1749-6632.2000.tb06651.x

29. Wei M., Brandhorst S., Shelehchi M., Mirzaei H., Cheng C.W., Budniak J.et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci. Transl. Med. 2017;9(377):eaai8700. DOI: 10.1126/scitranslmed.aai8700

30. Jiang Y., Tang Z., Zhu X., Xiao B., Tian H., Lei X. et al. Non-invasive omics analysis delineates molecular changes in water-only fasting and its sex-discriminating features in metabolic syndrome patients. Med. Comm. (2020). 2023;4(6):e393. DOI: 10.1002/mco2.393

31. Vitale G., Brugts M.P., Ogliari G., Castaldi D., Fatti L.M., Varewijck A.J. et al. Low circulating IGF-I bioactivity is associated with human longevity: fi ndings in centenarians’ off spring. Aging (Albany NY). 2012;4(9):580–589. DOI: 10.18632/aging.100484

32. Thissen J.P., Ketelslegers J.M., Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocr. Rev.1994;15(1):80–101. DOI: 10.1210/edrv-15-1-80

33. Fontana L., Partridge L., Longo V.D. Dietary restriction, growth factors and aging: from yeast to humans. Science. 2010;328(5976):321–326. DOI: 10.1126/science.1172539

34. Fontana L., Weiss E.P., Villareal D.T., Klein S., Holloszy J.O. Longterm eff ects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008;7(5):681–687. DOI: 10.1111/j.1474-9726.2008.00417.x

35. Jamshed H., Beyl R.A., Della Manna D.L., Yang E.S., Ravussin E., Peterson C.M. Early time-restricted feeding improves 24-hour glucose levels and aff ects markers of the circadian clock, aging, and autophagy in humans. Nutrients. 2019;11(6):1234. DOI: 10.3390/nu11061234

36. Nencioni A., Caff a I., Cortellino S., Longo V.D. Fasting and cancer: molecular mechanisms and clinical application. Nat. Rev. Cancer. 2018;18(11):707–719. DOI: 10.1038/s41568-018-0061-0

37. Salvioli S., Capri M., Bucci L., Lanni C., Racchi M., Uberti D., Memo M., Mari D., Govoni S., Franceschi C. Why do centenarians escape or postpone cancer? The role of IGF-1, infl ammation and p53. Cancer Immunol. Immunother. 2009;58(12):1909–17. DOI: 10.1007/s00262-008-0639-6

38. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., Wei M., Madia F., Cheng C.W. et al. Growth hormone receptor defi ciency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 2011;3(70):70ra13. DOI: 10.1126/scitranslmed.3001845

39. Shevah O., Laron Z. Patients with congenital defi ciency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res. 2007;17(1):54–57. DOI: 10.1016/j.ghir.2006.10.007

40. de Groot S., Lugtenberg R.T., Cohen D., Welters M.J.P., Ehsan I., Vreeswijk M.P.G. et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat. Commun. 2020;11(1):3083– 3093. DOI: 10.1038/s41467-020-16138-3

41. Safdie F.M., Dorff T., Quinn D., Fontana L., Wei M., Lee C., Cohen P., Longo V.D. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009;1(12):988–1007. DOI: 10.18632/aging.100114

42. Ferro Y., Maurotti S., Tarsitano M.G., Lodari O., Pujia R., Mazza E. et al. Therapeutic fasting in reducing chemotherapy side eff ects in cancer patients: a systematic review and meta-analysis. Nutrients. 2023;15(12):2666. DOI: 10.3390/nu15122666

43. Zhong Z., Zhang H., Nan K., Zhong J., Wu Q., Lu L. et al. Fastingmimicking diet drives antitumor immunity against colorectal cancer by reducing iga-producing cells. Cancer Res. 2023;83(21):3529– 3543. DOI: 10.1158/0008-5472.CAN-23-0323